Lv3
368 积分 2025-11-08 加入
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
22天前
已完结
Targeting intratumoral heterogeneity in pancreatic cancer with sequential TIL infusions
1个月前
已完结
Fast tumor-infiltrating lymphocytes (TILs): rapid manufacture of an adoptive cellular therapeutic from pleural infiltrating T cells for intrapleural administration
1个月前
已完结
Expansion of tumor-infiltrating lymphocytes in non-small cell lung cancer: Clinical potential and efficacy in EGFR mutation subsets
1个月前
已完结
MicroRNAs: Emerging oncogenic and tumor-suppressive regulators, biomarkers and therapeutic targets in lung cancer
1个月前
已完结
Navigating the Landscape of Resistance Mechanisms in Antibody–Drug Conjugates for Cancer Treatment
4个月前
已完结
Beyond cytotoxic potency: disposition features required to design ADC payload
5个月前
已完结
皖公网安备34019202002308
